Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may improve OS and RFS versus historical no-maintenance outcomes in R/R ...
RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...
TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and ...
Factors associated with occurrence of acute leukemias and myelodyplastic neoplasms as seen at the Kenyatta National Hospital, Nairobi, Kenya. Real-world adherence and tolerability of FLT3 inhibitors ...
AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral ...
Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal ...
NUP98-NSD1 and NUP98-KDM5A fusions are linked to poor prognosis in AML, affecting OS and EFS significantly. NUP98-NSD1 is more common in pediatric AML, necessitating alternative detection methods like ...
Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses rapidly without treatment. The National Cancer Institute estimates 20,800 new cases of AML will be diagnosed ...
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results